Developmental changes in human liver CYP2D6 expression

被引:106
|
作者
Stevens, Jeffrey C. [5 ]
Marsh, Sandra A. [5 ]
Zaya, Matthew J. [5 ]
Regina, Karen J. [5 ]
Divakaran, Karthika [2 ,3 ,4 ]
Le, Min [2 ,3 ,4 ]
Hines, Ronald N. [1 ,2 ,3 ,4 ]
机构
[1] Med Coll Wisconsin, TBRC, CRI, CPPT, Milwaukee, WI 53226 USA
[2] Med Coll Wisconsin, Dept Pediat, Milwaukee, WI 53226 USA
[3] Med Coll Wisconsin, Dept Pharmacol Toxicol, Milwaukee, WI 53226 USA
[4] Childrens Hosp & Hlth Syst, Milwaukee, WI USA
[5] Pfizer Corp, Global Res & Dev, Chesterfield, MO USA
关键词
D O I
10.1124/dmd.108.021873
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Within the human cytochrome P450 family, specific forms show developmental expression patterns that can affect drug clearance, efficacy, and safety. The objective of this study was to use dextromethorphan O-demethylase activity and quantitative Western blotting to identify CYP2D6 developmental expression patterns in a large (n = 222) and developmentally diverse set of pediatric liver samples. Immunodetectable levels of CYP2D6 protein determined for selected samples across all age categories showed a significant correlation with the corresponding dextromethorphan O-demethylase activity. Of gender, ethnicity, postmortem interval, and genotype, only increasing gestational age was associated with CYP2D6 activity and protein content in prenatal samples. In contrast, both age and genotype were associated with CYP2D6 expression in postnatal samples. CYP2D6 expression in liver samples from neonates less than 7 days of age was higher than that observed in first and second trimester samples, but not significantly higher than third trimester fetal samples. In contrast, expression in postnatal samples greater than 7 days of age was substantially higher than that for any earlier age category. Higher CYP2D6 expression also was observed in liver samples from Caucasians versus African Americans. Finally, using phenotype categories inferred from genotype, CYP2D6 activity was higher in postnatal samples predicted to be extensive or intermediate metabolizers versus poor metabolizers. These results suggest that age and genetic determinants of CYP2D6 expression constitute significant determinants of interindividual variability in CYP2D6-dependent metabolism during ontogeny.
引用
收藏
页码:1587 / 1593
页数:7
相关论文
共 50 条
  • [1] EXPRESSION OF CYP2D6 IN DEVELOPING HUMAN LIVER
    TRELUYER, JM
    JACQZAIGRAIN, E
    ALVAREZ, F
    CRESTEIL, T
    EUROPEAN JOURNAL OF BIOCHEMISTRY, 1991, 202 (02): : 583 - 588
  • [2] A frequent CYP2D6 variant promotes skipping of exon 3 and reduces CYP2D6 protein expression in human liver samples
    Collins, Joseph M. M.
    Lester, Hannah
    Shabnaz, Samia
    Wang, Danxin
    FRONTIERS IN PHARMACOLOGY, 2023, 14
  • [3] Evidence for CYP2D6 expression in human lung
    Lo Guidice, JM
    Marez, D
    Sabbagh, N
    Legrand-Andreoletti, M
    Spire, C
    Alcaïde, E
    Lafitte, JJ
    Broly, F
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1997, 241 (01) : 79 - 85
  • [4] Interactions of amphetamine analogs with human liver CYP2D6
    Wu, DF
    Otton, SV
    Inaba, T
    Kalow, W
    Sellers, EM
    BIOCHEMICAL PHARMACOLOGY, 1997, 53 (11) : 1605 - 1612
  • [5] Human liver CYP2D6 genotype, full-length mRNA, and activity, assessed with a novel CYP2D6 substrate
    Bodor, M
    McConnachie, L
    Kowdley, K
    Levy, A
    Tun, B
    Thummel, K
    Phillips, B
    Bajpai, M
    Chi, V
    Esmay, JD
    Shen, DD
    Ho, RJY
    DRUG METABOLISM REVIEWS, 2004, 36 : 113 - 113
  • [6] Analysis of CYP2D6 expression in human lung: Implications for the association between CYP2D6 activity and susceptibility to lung cancer
    Kivisto, KT
    Griese, KU
    Stuven, T
    Fritz, P
    Friedel, G
    Kroemer, HK
    Zanger, UM
    PHARMACOGENETICS, 1997, 7 (04): : 295 - 302
  • [7] Influence of donor and recipient genotypes on CYP2D6 phenotype after liver transplantation:: a study of mutations CYP2D6*3 and CYP2D6*4
    Monek, O
    Paintaud, G
    Bechtel, Y
    Miguet, JP
    Mantion, G
    Bechtel, PR
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1998, 54 (01) : 47 - 52
  • [8] Influence of donor and recipient genotypes on CYP2D6 phenotype after liver transplantation: a study of mutations CYP2D6*3 and CYP2D6*4
    O. Monek
    G. Paintaud
    Y. Bechtel
    J. P. Miguet
    G. Mantion
    P. R. Bechtel
    European Journal of Clinical Pharmacology, 1998, 54 : 47 - 52
  • [9] Transcriptional Regulation of CYP2D6 Expression
    Pan, Xian
    Ning, Miaoran
    Jeong, Hyunyoung
    DRUG METABOLISM AND DISPOSITION, 2017, 45 (01) : 42 - 48
  • [10] IN VITRO COMPARATIVE INHIBITORY PROFILES OF SEVERAL CYP2D6 INHIBITORS AND METABOLIC CAPABILITIES OF CYP2D6*1, CYP2D6*2, CYP2D6*10, AND CYP2D6*17 ON TRAMADOL METABOLISM
    Nahid, N.
    Kanumuri, S.
    Sharma, A.
    Wang, D.
    Johnson, J.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2024, 115 : S74 - S75